Evidence map›Paper›PMID 28494528›Full record

ArticleClinical and molecular hepatology2017

A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function.

Hyun Yang, Hyun Young Woo, Soon Kyu Lee, Ji Won Han, Bohyun Jang, Hee Chul Nam, Hae Lim Lee, Sung Won Lee, Do Seon Song, Myeong Jun Song and 7 more

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and molecular hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Hyun YangDepartment of Internal Medicine, The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Hyun Young WooDepartment of Internal Medicine and Medical Research Institute, Pusan National University College of Medicine, Pusan, Korea.
Soon Kyu LeeDepartment of Internal Medicine, The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Ji Won HanDepartment of Internal Medicine, The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Bohyun JangDepartment of Internal Medicine, The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Hee Chul NamDepartment of Internal Medicine, The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Hae Lim LeeDepartment of Internal Medicine, The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Sung Won LeeDepartment of Internal Medicine, The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Do Seon SongDepartment of Internal Medicine, The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Myeong Jun SongDepartment of Internal Medicine, The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Jung Suk OhDepartment of Radiology, The Catholic University of Korea, Seoul, Korea.
Ho Jong ChunDepartment of Radiology, The Catholic University of Korea, Seoul, Korea.
Jeong Won JangDepartment of Internal Medicine, The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Angelo LozadaDepartment of Internal Medicine, Makati Medical Center, Manila, Philippines.
Si Hyun BaeDepartment of Internal Medicine, The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0003-1727-7842
Jong Young ChoiDepartment of Internal Medicine, The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Seung Kew YoonDepartment of Internal Medicine, The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Catholic University of Korea · KRMakati Medical Center · PHPusan National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsMetronomic chemotherapy (MET) is frequently administered in comparatively low doses as a continuous chemotherapeutic agent. The aim of this study was to evaluate the feasibility and overall survival (OS) of MET compared to sorafenib for advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT).

methodsA total of 54 patients with advanced HCC and PVTT who had undergone MET were analyzed between 2005 and 2013. A total of 53 patients who had undergone sorafenib therapy were analyzed as the control group. The primary endpoint of this study was OS.

resultsThe median number of MET cycles was two (1-15). The OS values for the MET group and sorafenib group were 158 days (132-184) and 117 days (92-142), respectively (

conclusionsMET was associated with more favorable outcomes in terms of overall survival than was sorafenib in patients with advanced HCC with PVTT, especially in patients with poor liver function. Therefore, MET can be considered as a treatment option in patients with advanced HCC with PVTT and poor liver function.

Indexed as

AdultAgedalpha-FetoproteinsAntineoplastic AgentsCarcinoma, HepatocellularCisplatinDrug Administration ScheduleFemaleFluorouracilHumansHyperbilirubinemiaLiverLiver NeoplasmsMaleMiddle AgedNeoplasm Stagingalpha-FetoproteinsAntineoplastic AgentsCisplatinFluorouracilNiacinamidePhenylurea CompoundsSorafenibAdministration, MetronomicCarcinoma, HepatocellularPortal veinSorafenibThrombosis

Identifiers

PMID28494528
PMCPMC5497665
OpenAlexW2614026296

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.